Last reviewed · How we verify
COVID-19 Standard Therapy
At a glance
| Generic name | COVID-19 Standard Therapy |
|---|---|
| Sponsor | Catalysis SL |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (PHASE2)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Nasal Swab Objective and Statistical Evaluation (NOSE Study)
- Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients (NA)
- COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II) (PHASE2)
- Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. (PHASE2)
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-19 Standard Therapy CI brief — competitive landscape report
- COVID-19 Standard Therapy updates RSS · CI watch RSS
- Catalysis SL portfolio CI